The selective capture and sequencing of coding regions in the genome is a powerful and cost effective tool for researchers wanting to identify disease-causing mutations. Ambry Genetics has extensive experience with exome sequencing in both a research and clinical setting. As early adopters of NGS technology and advanced target enrichment techniques, Ambry’s experience and knowledge is hard to beat. Ambry was the 3rd Certified Service Provider (CSPro) lab in the world for Illumina NGS sequencing and 1st in the world for Agilent SureSelect Target Enrichment. In 2011, Ambry was the first company to offer CLIA-approved Whole Exome Sequencing for clinical diagnostics.